Our recent studies in colon cancer, as well as another thorough study by Gonzalez et al., in breast cancer, reiterate that loss of EZH2 results in primary tumor growth inhibition, whereas our current observation in TNBC shows no significant impact of EZH2 in primary tumor growth12,62. Here, EZH2 is linked to malignant colon neoplasm.